Potential impact of nirsevimab and bivalent maternal vaccine against RSV bronchiolitis in infants: A population-based modelling study
Background: A new monoclonal antibody (nirsevimab; Beyfortus®) and a bivalent prefusion RSV vaccine (Abrysvo®) for maternal immunization have been approved recently. This is a modelling study to estimate the potential impact of different immunization programs with these products on RSV-bronchiolitis...
Na minha lista:
Principais autores: | , , , , , |
---|---|
Formato: | Livro |
Publicado em: |
Elsevier,
2024-08-01T00:00:00Z.
|
Assuntos: | |
Acesso em linha: | Connect to this object online. |
Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|
Internet
Connect to this object online.3rd Floor Main Library
Número de Chamada: |
A1234.567 |
---|---|
Cópia 1 | Disponível |